(Q34382875)

1 August 2017

1 reference

title

New perspectives on macrolide antibiotics (English)

1 reference

1 August 2017

0 references

Pechère JC

1

1 reference

1 August 2017

publication date

1 January 2001

1 reference

International Journal of Antimicrobial Agents

1 August 2017

published in

1 reference

1 August 2017

volume

18 Suppl 1

1 reference

1 August 2017

page(s)

S93-7

1 reference

Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Single-dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Randomised controlled trial of single-dose azithromycin in treatment of trachoma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Distribution of Chlamydia pneumoniae infection in the athersclerotic carotid artery

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Chlamydia pneumoniae in atherosclerotic tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Antibiotics and risk of subsequent first-time acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

In-vitro activities of clarithromycin and other antimicrobial agents against Helicobacter pylori isolated from children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Eradication of Helicobacter pylori with clarithromycin and omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

In vitro activity of azithromycin against bacterial enteric pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Intracellular accumulation of azithromycin by cultured human fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Effect of Macrolide Antibiotics on Human Serum-Bactericidal Sensitivity of Pseudomonas aeruginosa S-6

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Effects of azithromycin on malariometric indices in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900393-4

7 January 2021

10.1016/S0924-8579(01)00393-4

Identifiers

DOI

1 reference

1 August 2017

1 reference